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Abete et al.) having been reported. This variation in life span is not
unique to the rabbit, and it underscores a crucial caveat: life span
or age is, in itself, a poor predictor of the aging process (4). Thus,
evaluation of established biomarkers of aging (4)—rather than
attempts to equate, from maximum life spans, relative ages among
species—may represent a more germane approach in addressing
this question.
We observed significant myocyte hypertrophy and myocardial
fibrosis—the morphologic hallmarks of cardiovascular aging—in
four-year-old versus young adult rabbits (1). For example, left
ventricular collagen content was 10.8  0.5% (SD 1.8%) versus
6.2  0.3% (SD 1.2%), respectively—a mean 1.7-fold increase
(range: 1.2- to 2.5-fold, computed from the SD values) in fibrosis.
Abete and colleagues contend that our results are qualitatively, but
not quantitatively, similar to those observed in the2-year-old rat,
an accepted model of senescence. We find, however, that despite
methodologic differences among studies, our results fall within the
range of data reported for rats (5,6)—including those from
Anversa et al. (5), in which collagen volume fraction was 16  4%
(mean  SD) versus 8  2% in 29- versus 4-month-old animals,
corresponding to a twofold increase (range: 1.2- to 3.3-fold) in
fibrosis. (Of note, the values of 7% and 22% cited by Abete et al.
were obtained in the right, rather than the left, ventricle (5)). With
regard to hypertrophy, our 1.3-fold increase in myocyte cross-
sectional area compares favorably with the 1.4-fold increase
seen in 23-month-old versus 7-month-old rats (6), and, inter-
estingly, with human autopsy data (death unrelated to cardio-
vascular disease) showing, via regression analysis, a 1.3-fold
increase in myocyte volume between 20 and 75 years of age (7).
Finally, the four-year-old rabbits displayed a third, functional
hallmark of cardiovascular aging—loss of responsiveness to
beta-adrenergic stimulation (1).
There is an emerging consensus that, in isolated buffer-perfused
rat heart, the efficacy of infarct size reduction with PC wanes with
increasing age (8,9). In contrast—and contrary to the correspon-
dents’ interpretation of our data—we found sustained, 49%, 58%
and 50% reductions of infarct size in PC rabbits versus age-
matched adult, two-year-old and four-year-old controls (1). Does
this difference in outcome make the four-year-old rabbit, exhibit-
ing definitive biomarkers of cardiovascular aging, the “wrong”
model? We believe this disparity is not a question of “right” versus
“wrong” models. Indeed, recent preliminary evidence from isolated
human myocardial samples—arguably a “right” model—revealed
persistent PC-induced protection even in cohorts aged 70 to 90
years old (10). Rather, this may reflect underlying mechanistic
difference(s) among models/species that warrant resolution.
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Revascularizing Chronic Total Occlusions:
What About the Coronary
Collaterals and Myocardial Viability Story?
With reference to the study by Suero et al. (1), I wish to make the
following comments:
1. Although there was a 10-year survival advantage in patients
who had a successful percutaneous coronary intervention (PCI) to
a chronic total occlusion (CTO), this study did not look at the
relation of such a survival advantage following a successful revas-
cularization to the presence of viability of infarcted myocardium in
the 54% with a previous myocardial infarction (MI). This rela-
tionship is expected.
2. It may not be correct to state that all CTOs benefit from
revascularization. I suspect that the survival advantage in this
cohort came mainly from improvement in left ventricular (LV)
function following improvement in contractility of viable infarcted
myocardial segments (2). In support, there is data from some
uncontrolled surgical series to show that improved survival in
patients with LV dysfunction correlates with the presence of
myocardial viability in several LV segments (3).
This will be the subject of evaluation in the Total Occlusion
Study of Canada (TOSCA-2) substudy of the ongoing Occluded
Artery Trial (OAT), which follows the previously published
TOSCA study (4). Interestingly, this survival advantage occurred
although only 10% of patients received a stent. A significant
reduction in restenosis following stenting compared with balloon
angioplasty of a CTO was reported in the TOSCA study.
3. The role of collaterals in this situation has always been an area
both of controversy and interest. This would perhaps be a good
opportunity to review the data to see whether the survival advan-
tage reported in this study correlates with the presence of angio-
graphic collaterals, especially as there is now data to show that
collateral flow assessed invasively (5) does correlate with viability of
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infarcted myocardium, as was first proposed in Chugh’s hypothesis
(6).
An important relevant observation is that the study population
had a mean duration of occlusion of the CTO vessel of 12  20
months. This study is therefore more likely to be able to answer the
often asked question about the role of angiographic collaterals in
predicting myocardial viability. This is because it is believed that
CTOs such as these give adequate time for collateral development,
unlike the recent occlusions studied using contrast echocardiogra-
phy soon after acute MI (7).
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REPLY
Dr. Chugh’s comments regarding our chronic total occlusion
(CTO) experience are well stated and germane to our findings.
Our intent for this project was to investigate the association
between long-term survival and successful recannulization of a
CTO. In order to demonstrate this association, a matched cohort
was developed using a propensity-scoring model. Thus, the com-
parison groups were remarkably similar with respect to baseline
covariates that are known predictors of long-term survival. In fact,
the survival curves for the matched cohort and the CTO group
were markedly similar. Only those patients with a successful
recannulization of a CTO demonstrated a survival benefit. This
link persisted following multivariate adjustment and was identified
in the failed percutaneous coronary intervention (PCI) cohort in
whom successful surgical recannulization of the CTO was per-
formed.
In our opinion, this body of work clearly identifies a group of
patients in whom successful PCI is associated with improved
long-term survival. There is no question that further work needs to
be performed on the mechanism of survival. Two leading theories
are certainly collateral flow and viability. Other plausible explana-
tions that are worthy of future investigation include the effect of
successful recannulization upon the incidence of sudden cardiac
death, left ventricular remodeling, and identification of certain
clinical patient subsets that are associated with an improved
survival following CTO and recannulization. For example, patients
with a history of diabetes mellitus have been demonstrated to have
a decreased incidence of collateral vessel formation despite abnor-
mal coronary atherosclerosis. However, patients with a history of
diabetes mellitus derived substantial benefit from a successful
recannulization of a chronic total occlusion in our study (data not
shown). To further our understanding of this cohort, we have
identified 558 patients from our nuclear database with a peri-
procedural radionucleotide perfusion study. We are hopeful that
this additional information will result in an enhanced understand-
ing of the survival benefit of successful recanalization of a CTO.
Finally, Dr. Chugh’s comments are insightful and, it is hoped,
will prompt future investigation into the mechanism of survival
benefit associated with a successful recannulization of a CTO.
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Is a High Hematocrit Level
Good for Patients With Heart Failure?
We were interested to read the article by Al-Ahmad and colleagues
(1) regarding the prognostic value of impaired renal function and
anemia in patients with left ventricular (LV) dysfunction, pub-
lished in the Journal of the American College of Cardiology. The
investigators report that reduced kidney function and a low
hematocrit are independent risk factors for increased all-cause
mortality in patients with LV dysfunction, with there being a
synergistic relationship between the two parameters. The results
from this study, together with other work in the field (2), may have
important clinical implications for the management of patients
with chronic heart failure (CHF). However, we believe several
points deserve further consideration.
The prognostic benefits of treating anemia in CHF and whether
there is an optimal range of hematocrit for survival are not known.
In the Framingham study, the impact of hematocrit on all-cause
death as well as morbidity and mortality due to cardiovascular
disease was shown to follow a U-shaped curve (3). Other prospec-
tive epidemiological studies of healthy populations have shown
that the lowest mortality rate correlates with a mid-range hemat-
ocrit level in both genders and at all ages (4). Al-Ahmad et al. (1)
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